Peptide ReadinessDiscuss your requirements
Back to database

LATE STAGE PIPELINE

Zenagamtide

Formerly amycretin, this single molecule peptide is being developed in injectable and oral forms.

Conceptual three-dimensional molecular signature for Zenagamtide; not an exact chemical structure.
Unimolecular GLP-1 and amylin receptor agonist peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade BPhase 3 / late stage development
FDA STATUS

Investigational; not FDA approved

MHRA / UK LICENCE

Investigational; no UK marketing authorisation

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access

PRIVATE LAWFUL USE CONTEXT

Not a licensed UK treatment

EVIDENCE MATURITY

Phase 2 signal with registered Phase 3 development

DEVELOPMENT PHASE

Phase 3 / late stage development

MARKET EXPOSURE

Emerging

PROFESSIONAL RELEVANCE

Track Phase 3 efficacy, tolerability, oral development and likely differentiation from combination therapies.

Product, formulation and indication

No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.

Status history

Production baseline verification recorded.

Phase 3 obesity programme initiated in 2026

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.